CINECA IRIS Institutional Research Information System

CHEGAEV, Konstantin
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.539
EU - Europa 2.893
AS - Asia 1.831
SA - Sud America 51
AF - Africa 27
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 6
Totale 10.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.457
CN - Cina 964
IT - Italia 786
IE - Irlanda 425
SG - Singapore 353
DE - Germania 303
SE - Svezia 297
FR - Francia 202
FI - Finlandia 173
UA - Ucraina 173
PL - Polonia 127
GB - Regno Unito 124
AT - Austria 114
KR - Corea 105
JP - Giappone 69
CA - Canada 68
IN - India 67
ID - Indonesia 61
VN - Vietnam 60
RU - Federazione Russa 53
TW - Taiwan 45
BR - Brasile 33
ES - Italia 30
HK - Hong Kong 24
TR - Turchia 24
NL - Olanda 21
MX - Messico 14
AU - Australia 12
BE - Belgio 12
EG - Egitto 12
CH - Svizzera 10
NZ - Nuova Zelanda 10
GR - Grecia 8
JO - Giordania 8
IR - Iran 7
SN - Senegal 7
AR - Argentina 6
EU - Europa 6
MY - Malesia 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
CL - Cile 5
DK - Danimarca 5
PT - Portogallo 5
EC - Ecuador 4
NO - Norvegia 4
RO - Romania 4
UZ - Uzbekistan 4
CY - Cipro 3
HU - Ungheria 3
IQ - Iraq 3
MU - Mauritius 3
PH - Filippine 3
AF - Afghanistan, Repubblica islamica di 2
AM - Armenia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
HR - Croazia 2
IL - Israele 2
NG - Nigeria 2
PK - Pakistan 2
QA - Qatar 2
SA - Arabia Saudita 2
SI - Slovenia 2
UY - Uruguay 2
CI - Costa d'Avorio 1
CO - Colombia 1
KG - Kirghizistan 1
LB - Libano 1
LT - Lituania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 10.369
Salva come PNG Salva come JPEG
Città #
Ann Arbor 505
Fairfield 501
Chandler 466
Beijing 433
Dublin 420
Ashburn 363
Singapore 282
Santa Clara 268
Houston 251
Woodbridge 220
Torino 218
Wilmington 196
Seattle 173
Dearborn 160
Pisa 152
Cambridge 150
Villeurbanne 121
Jacksonville 120
Warsaw 118
Nyköping 115
Vienna 108
Medford 107
Princeton 93
Redwood City 84
Columbus 81
Fremont 69
Jakarta 57
Shanghai 40
Munich 38
Boston 36
Guangzhou 36
Taipei 36
Turin 34
Hangzhou 29
Helsinki 29
Dong Ket 28
Milan 28
Boardman 26
New York 26
San Diego 26
Toronto 25
Zhengzhou 25
Nanjing 24
Jinan 21
Ottawa 21
Siena 21
Tokyo 21
Washington 20
Verona 19
Norwalk 18
Wuhan 18
Kunming 16
Nuremberg 16
Toledo 15
Shenyang 13
Brussels 12
Changsha 11
Naples 11
Upper Marlboro 11
Xian 11
Florence 10
Chengdu 9
Hefei 9
Nürnberg 9
Phoenix 9
Rome 9
Falls Church 8
Guiyang 8
Hebei 8
Moscow 8
Nanchang 8
Pune 8
Rivoli 8
Silver Spring 8
Buffalo 7
Cairo 6
Changchun 6
Dallas 6
Farmington 6
Hong Kong 6
Lachine 6
London 6
Los Angeles 6
Nanning 6
Tianjin 6
Amman 5
Bari 5
Buenos Aires 5
Catania 5
Chioggia 5
Chongqing 5
Des Moines 5
Donetsk 5
Fort Lauderdale 5
Granada 5
Leinì 5
Philadelphia 5
San Jose 5
Tappahannock 5
Woodside 5
Totale 6.853
Salva come PNG Salva come JPEG
Nome #
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 421
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 308
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 300
New furoxan derivatives for the treatment of ocular hypertension 285
Doxorubicin-antioxidant multitarget drugs 279
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. 271
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease 266
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins 262
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 257
Edaravone derivatives containing NO-donor functions 221
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins 199
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis 198
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein 190
Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies 183
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells 183
Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis 178
New nitric oxide or hydrogen sulfide releasing aspirins 177
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs 174
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity 172
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants 164
Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents 164
Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Riperfusion Injury 158
Direct introduction of cyano group on furoxan ring 148
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension 145
Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells 142
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties 138
Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors 135
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug 135
A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion 134
Amphiphilic NO-Donor Antioxidants 134
Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors 133
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 129
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization 128
Multitarget Drugs: Focus on the NO-donor hybrid drugs 127
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties 124
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile 116
Aceclofenac-galactose conjugate: design, synthesis, characterization and pharmacological and toxicological evaluations 114
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro 111
Leishmanicidal Activity of Novel Synthetic Furoxan and Benzofuroxan Derivatives 110
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 109
Mitochondrial delivery of phenol substructure triggers mitochondrial depolarization and apoptosis of cancer cells 109
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma 106
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin. 91
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands 91
Novel Organic Nitrate Esters 90
NO-Donor Furoxans Containing a Sulphonamide Moiety and Related Furazans as Potent Carbonic Anhydrase Inhibitors 88
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations 88
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance. 86
Amphiphile NO-donor antioxidants as polivalent drugs 84
NO-Donor Cyanines As Potential Anti-Alzheimer Drugs 80
PREPARATION AND CHARACTERIZATION OF LIPOSOMES CONTAINING A NEW ANTHRACYCLINE DERIVATIVE 79
NITRIC OXIDE DONOR DOXORUBICINS: A USEFUL STRATEGY TO ADDRESS THE PROBLEM OF MDR IN CANCER THERAPY 76
Synthesis of new heterocyclic sulfamides 75
PHENYLSULFONYL FUROXANS AS MODULATORS OF MULTIDRUGRESISTANCE-ASSOCIATED PROTEIN-1 AND P-GLYCOPROTEIN 74
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells 74
Highly diastereoselective synthesis of 2-monosubstituted 1R,5S(1S,5R)-glycoluriles on the basis of S- and R-N-carbamoyl-alpha-amino acids 71
Multitarget Drugs: No-Donor Doxorubicins 71
Novel amphiphilic nitric oxide releasing antioxidants: NMR spectroscopic study of their interaction with biomembrane models 69
Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts 67
Novel NO-donor Doxorubicins 67
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors 67
Unsymmetrically Substituted Furoxans. Part 19. Methyl and Phenylfuroxansulfonic Acids and Related Sulfonamides 64
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER 64
Reactions of sulfonamides with 4,5-dihydroxyimidazolidin-2-ones 63
NOVEL SEMISYNTHETIC DOXORUBICINS WITH REDUCED CARDIOTOXICITY 63
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE 63
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation 63
NO donor - melatonins: a new class of potential antiatherosclerosis agents 62
Preparation and characterization of liposomes containing a new anthracycline derivative. 61
Multitarget drugs: NO-donor doxorubicins 59
New functional glycoluril derivatives 54
Vasodilating profile of a new series of analogues of GTN 54
Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers 54
Nitric oxide release by an edavarone derivative containing NOdonor furoxan moiety contributes to the resolution of renal injury after ischemia/reperfusion in the rat 53
The N-silylation reaction of 2,4,6-trialkyl-2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones 53
Comparative Study of Different H2S Donors as Vasodilators and Attenuators of Superoxide-Induced Endothelial Damage 52
Nitric oxide donor-doxorubicins as mdr reversing agents 51
Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4′-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein 50
Tolerance profile of new organic nitrates with antioxidant properties 48
Screening for potential hazard effects from a multitarget anthracycline on the cardiovascular system 48
Synthesis of 2-monofunctionalized 2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones 47
MITOCHONDRIAL-TARGETING NITROOXYDOXORUBICIN: EFFECTS ON P-GLYCOPROTEIN AND ASSESSMENT OF THEIR VASCULAR EFFECTS 44
IN VITRO CARDIOVASCULAR TOXICITY RISK ASSESSMENT OF NOVEL H2S-DONATING ANTHRACYCLINE 44
Reactions of N-alkylglycolurils with electrophilic reagents 40
N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation 37
NO-donor aspirin derivatives 37
Screening for potential hazard effects from multitarget anthracyclines on vasculature 36
Naked and Decorated Nanoparticles Containing H2S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells 35
NO release regulated by doxorubicin as the green light-harvesting antenna 35
SCREENING FOR POTENTIAL HAZARD EFFECTS FROM MULTITARGET ANTHRACYCLINE ON THE CARDIOVASCULAR SYSTEM 34
Planning, synthesis and anti-Mycobacterium tuberculosis activity of N-oxide derivatives 34
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study 34
Synthesis, physical-chemical and pharmacological studies of new organic nitrates as novel potent vasodilatators 31
Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells 25
Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature 24
New lipophilic organic nitrates: Candidates for chronic skin disease therapy 22
In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin 17
Multitarget antioxidant NO-donor organic nitrates: a novel approach to overcome nitrates tolerance 15
Development of targeted lipid nanoparticles for the combined therapy of triple negative breast cancer: Can curcumin and 6-aminoflavone promote doxorubicin in vitro efficacy? 7
Totale 10.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.248
article - articoli 0
book - libri 0
conference - conferenze 6.064
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.312
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020913 0 0 0 0 0 0 165 131 198 181 130 108
2020/20211.180 98 92 86 63 115 74 65 86 170 114 83 134
2021/20221.403 87 84 99 133 69 49 101 87 59 88 322 225
2022/20231.542 148 145 32 118 113 374 214 86 160 56 57 39
2023/2024904 84 131 56 35 71 168 42 42 13 85 67 110
2024/20251.048 52 113 116 172 421 153 21 0 0 0 0 0
Totale 10.702